BeiGene Ltd. (BGNE) saw its shares surge 5.24% on Wednesday, outperforming the broader market, after the European Commission approved the company's cancer treatment TEVIMBRA (tislelizumab) for expanded use in the region.
The approval allows TEVIMBRA, in combination with chemotherapy, to be used as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The decision was based on positive results from two Phase 3 studies that demonstrated a statistically significant overall survival benefit for patients treated with TEVIMBRA plus chemotherapy.
Investors welcomed the regulatory approval, which expands the addressable market for BeiGene's cornerstone solid tumor therapy. The company highlighted the urgent need for effective treatment options in these cancer types, citing the poor prognosis for patients diagnosed with advanced gastric and esophageal cancers.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。